How much funding has Caribou Biosciences raised?

Caribou Biosciences has raised $181.0M in total funding, most recently a Corporate Round.

Who are Caribou Biosciences's investors?

Caribou Biosciences's investors include Pfizer Ventures, Fidelity Biosciences, AbbVie Ventures, Adage Capital, Avego Bioscience, 5 Prime Ventures.

When was Caribou Biosciences founded?

Caribou Biosciences was founded in 2011.

Where is Caribou Biosciences headquartered?

Caribou Biosciences is headquartered in Berkeley, California, United States.

What industry is Caribou Biosciences in?

Caribou Biosciences operates in Biotech, Healthcare, Life Sciences, Therapeutics.

How many employees does Caribou Biosciences have?

Caribou Biosciences has 51-200 employees.

Caribou Biosciences

IPO

Developing Sophisticated Allogeneic Cell Therapies

Public · Berkeley, United States · Founded 2011 · $181.0M raised

Headquarters: Berkeley, California
Employees: 51–200
Founded: 2011
Business Model: B2B
Website: cariboubio.com

Total Funding: $181.0M
Last Round: $25.0M Corporate RoundJul 2023
Rounds: 4
Type: Public

About

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) genome-editing platform enables superior precision for complex multiplex editing, including gene knockout and insertion. Caribou is advancing CB-010 and CB-011 as off-the-shelf allogeneic CAR-T cell therapies targeting hematologic malignancies.

Summary

Caribou Biosciences is a Biotech company based in Berkeley, United States, founded in 2011. It has raised $181.0M in total across 4 rounds, most recently a $25.0M Corporate Round round in Jul 2023. Investors include Pfizer Ventures, Fidelity Biosciences and AbbVie Ventures.

LinkedIn X (Twitter)